Blockade of programmed death-1 in young (New Zealand black × New Zealand white)F1mice promotes the activity of suppressive CD8 + T cells that protect from lupus-like disease

Journal of Immunology

Volumn 185, Issue 11, 2010, Pages 6563-6571

  Wong, Maida ^a   La Cava, Antonio ^a   Singh, Ram P ^a   Hahn, Bevra H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

AGING; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, SURFACE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOANTIBODIES; CD8-POSITIVE T-LYMPHOCYTES; CROSSES, GENETIC; DOWN-REGULATION; FEMALE; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFORMING GROWTH FACTOR BETA;

EID: 78650656619     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903401     Document Type: Article

References (30)

1. Sperling, A. I., and J. A. Bluestone. 1996. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol. Rev. 153:155-182.
2. Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203:883-895.
3. Fife, B. T., I. Guleria, M. Gubbels Bupp, T. N. Eagar, Q. Tang, H. Bour-Jordan, H. Yagita, M. Azuma, M. H. Sayegh, and J. A. Bluestone. 2006. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203:2737-2747.
4. Sharpe, A. H., E. J. Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8:239-245.
5. Okazaki, T., and T. Honjo. 2006. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27:195-201.
6. Brown, J. A., D. M. Dorfman, F. R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A. Greenfield, and G. J. Freeman. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170:1257-1266.
7. Mazanet, M. M., and C. C. Hughes. 2002. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169:3581-3588.
8. Blazar, B. R., B. M. Carreno, A. Panoskaltsis-Mortari, L. Carter, Y. Iwai, H. Yagita, H. Nishimura, and P. A. Taylor. 2003. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J. Immunol. 171:1272-1277.
9. Salama, A. D., T. Chitnis, J. Imitola, M. J. Ansari, H. Akiba, F. Tushima, M. Azuma, H. Yagita, M. H. Sayegh, and S. J. Khoury. 2003. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198:71-78.
10. [Published erratum appears in 2003 J. Exp. Med. 198:677.]
11. Prokunina, L., C. Castillejo-López, F. Oberg, I. Gunnarsson, L. Berg, V. Magnusson, A. J. Brookes, D. Tentler, H. Kristjansdóttir, G. Gröndal, et al. 2002. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32:666-669.
12. Wang, S. C., Y. J. Chen, T. T. Ou, C. C. Wu, W. C. Tsai, H. W. Liu, and J. H. Yen. 2006. Programmed death-1 gene polymorphisms in patients with systemic lupus erythematosus in Taiwan. J. Clin. Immunol. 26:506-511.
13. Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151.
14. Nishimura, H., T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, A. Mizoguchi, H. Hiai, N. Minato, and T. Honjo. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-322.
15. Singh, R. P., A. la Cava, and B. H. Hahn. 2008. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW) F1 mice by differentially regulating Foxp3 and PD1 molecules. J. Immunol. 180:2069-2080.
16. Hahn, B. H., R. P. Singh, A. la Cava, and F. M. Ebling. 2005. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J. Immunol. 175:7728-7737.
17. La Cava, A., F. M. Ebling, and B. H. Hahn. 2004. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White) F1 mice suppress in vitro production of antibodies to DNA. J. Immunol. 173:3542-3548.
18. Hahn, B. H., R. R. Singh, W. K. Wong, B. P. Tsao, K. Bulpitt, and F. M. Ebling. 2001. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum. 44:432-441.
19. Ohnishi, K., F. M. Ebling, B. Mitchell, R. R. Singh, B. H. Hahn, and B. P. Tsao. 1994. Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int. Immunol. 6:817-830.
20. Tsao, B. P., F. M. Ebling, C. Roman, N. Panosian-Sahakian, K. Calame, and B. H. Hahn. 1990. Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus. J. Clin. Invest. 85:530-540.
21. Singh, R. P., A. la Cava, M. Wong, F. M. Ebling, and B. H. Hahn. 2007. CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J. Immunol. 178:7649-7657.
22. Singh, R. R., F. M. Ebling, E. E. Sercarz, and B. H. Hahn. 1995. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J. Clin. Invest. 96:2990-2996.
23. Hahn, B. H. 2006. Overview of pathogenesis of systemic lupus erythematosus. In Dubois' Lupus Erythematosus. D. Wallace, and B. H. Hahn, eds. Lippincott Williams & Wilkins, Philadelphia, p. 46-53.
24. Kasagi, S., S. Kawano, T. Okazaki, T. Honjo, A. Morinobu, S. Hatachi, K. Shimatani, Y. Tanaka, N. Minato, and S. Kumagai. 2010. Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J. Immunol. 184:2337-2347.
25. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-548.
26. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
27. Trautmann, L., L. Janbazian, N. Chomont, E. A. Said, S. Gimmig, B. Bessette, M. R. Boulassel, E. Delwart, H. Sepulveda, R. S. Balderas, et al. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12:1198-1202.
28. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354.
29. Appay, V., D. F. Nixon, S. M. Donahoe, G. M. Gillespie, T. Dong, A. King, G. S. Ogg, H. M. Spiegel, C. Conlon, C. A. Spina, et al. 2000. HIV-specific CD8 (+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192:63-75.
30. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205-2213.